Cardiac and kidney hormones cure up to 86% of human small-cell lung cancers in mice

European Journal of Clinical Investigation

Volumn 38, Issue 8, 2008, Pages 562-570

  Eichelbaum, E J ^a   Sun, Y ^a   Alli, A A ^a   Gower Jr , W R ^a,b   Vesely, D L ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Metastasis; Natriuretic peptides; New therapeutics; Receptors; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; KALIURETIC PEPTIDE; LONG ACTING DRUG; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR A; NATRIURETIC PEPTIDE RECEPTOR C; URODILATIN; VASODILATOR AGENT;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY TEMPERATURE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CONTROLLED STUDY; DIARRHEA; DISTRESS SYNDROME; DRUG DOSE SEQUENCE; DRUG RECEPTOR BINDING; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; HYPOTENSION; KALIURESIS; LUNG METASTASIS; LUNG SMALL CELL CANCER; MOUSE; NAUSEA; NONHUMAN; PAIN; PRIORITY JOURNAL; SEIZURE; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; ATRIAL NATRIURETIC FACTOR; CARCINOMA, SMALL CELL; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM METASTASIS; PEPTIDE FRAGMENTS; PROTEIN PRECURSORS; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 47649105292     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.01978.x     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer Statistics, 2008. CA Cancer J Clin 2007 57 : 43 66.
2. Vaporciyan AA, Kies M, Stevens C, Komaki R, Roth JA. Cancer of the lung. In : Kufe DW, Pollock, RE, Weichselbaum, RR, Bast, RC, Gansler, TS, Holland, JF, Frei, E III, eds. Cancer Medicine, 6th edn. Hamilton, Ontario : BC Decker Inc. 2003, pp. 1385 445.
3. Kelley MJ, Johnson BE. Molecular biology of lung cancer. In : Mendlesohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia : W.B. Saunders Company 2nd edn 2001. pp. 260 87.
4. Brenner BM, Ballermann BJ, Gunning ME, Zeidel ML. Diverse biological actions of atrial natriuretic peptide. Physiol Rev 1990 70 : 665 99.
5. Vesely DL. Atrial natriuretic peptide prohormone gene expression: Hormones and diseases that upregulate its expression. IUBMB Life 2002 53 : 153 9.
6. Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol 2003 285 : F167 F177.
7. Vesely DL. Natriuretic hormones. In : The Kidney: Physiology and Pathophysiology, 4th edn. Alpern, RJ, Hebert, SC, eds. San Diego, CA : Elsevier/Academic Press, 2007, pp. 947 77.
8. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Alli AA, Solivan SR et al. Five cardiac hormones decrease the number of human small-cell cancer cells. Eur J Clin Invest 2005 35 : 388 98.
9. Vesely BA, Eichelbaum EJ, Alli AA, Sun Y, Gower WR Jr., Vesely DL. Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 2006 36 : 810 9.
10. Fisher ER, Palekar A, Paulson JD. Comparative histopathologic, histochemical, electron microscopy and tissue culture studies of bronchial carcinoids and oat cell carcinomas of lung. Am J Clin Pathol 1978 69 : 165 72.
11. Duguay D, Mercier F, Stagg J, Martineau D, Bramson J, Servant M et al. In vivo interferon regulatory factor 3-tumor suppressor activity in B16 melanoma tumors. Cancer Res 2002 62 : 5148 52.
12. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL et al. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 2007 21 : 445 52.
13. Gower WR Jr., Vesely BA, Alli AA, Vesely DL. Four peptides decrease human colon adenocarcinoma cell number and DNA synthesis via guanosine 3′5′-cyclic monophosphate. Int J Gastrointestinal Cancer 2005 36 : 77 88.
14. Vesely BA, Alli AA, Song S, Gower WR Jr., Sanchez-Ramos J, Vesely DL. Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 2005 35 : 700 10.
15. Simon GR, Turrisi A. Management of small cell lung cancer. ACCP Evidence-based clinical practice guidelines. Chest 2007 32 : 3245 395.
16. Vesely DL, Cornett LE, McCleod SL, Nash AA, Norris JS. Specific binding sites for prohormone atrial natriuretic peptides 1-30, 31-67, and 99-126. Peptides. 11 : 193 7.
17. Vesely DL, Arnold WC, Winters CJ, Sallman AL, Rico DM. Increased circulating concentration of the N-terminus of the atrial natriuretic prohormone in persons with pheochromocytomas. J Clin Endocrinol Metab 1990 71 : 1138 46.
18. Vesely DL, Sallman AL, Bayliss JM. Specific binding sites for pro atrial natriuretic factors 1-30, 31-67, and 99-126 on distal nephrons, proximal tubules, renal cortical and medullary membranes. Renal Physiol Biochem. 15 : 23 32.
19. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 2006 26 : 3217 22.
20. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006 26 : 4143 8.
21. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007 27 : 1387 92.
22. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007 27 : 3813 8.
23. Saba SR, Garces AH, Clark LC, Soto J, Gower WR Jr., Vesely DL. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 2005 53 : 989 95.
24. Alli AA, McCormick BZ, Gower WR Jr. Characterization of a novel polyclonal antibody against the C-type natriuretic peptide receptor. Am Soc Cell Biol 2007 47 : 290.